U24EY035102
Cooperative Agreement
Overview
Grant Description
Defining Bacterial Members of the Ocular Surface Microbiome and Assessing Stability Over Time - Project Summary
Recent studies have shown data suggesting that the ocular microbiome exists and influences ocular surface health and disease. Despite this, defining the "core" components of the ocular surface microbiome has been difficult, largely due to the low biomass nature of the eye, a lack of robust data sets, reliance only on next-generation sequencing (NGS), and the inability to show causal relationships between microbes and host physiology.
Herein, we have outlined a proposal that directly addresses these knowledge gaps and that will lay the foundation for future studies aimed at investigating how the ocular surface microbiome influences health and disease. We have recruited a multidisciplinary research team that consists of experts in clinical and basic ophthalmology research, microbiome of low biomass sites, and immunology.
With this team, we plan to first characterize the healthy human ocular microbiome in two geographic locations (Pittsburgh and Miami) longitudinally (0, 1 week, 3 months) using molecular techniques (DNA and RNA sequencing) and culturomics. While molecular techniques will provide us with the broadest consortia of bacteria, culturomics will provide us with viable bacteria that we plan to bank in the Campbell Laboratory, so that bacteria from healthy human eyes can be a resource for the community in future studies.
Next, because immunity is normally generated towards components of the microbiome that remain associated with the host for extended periods of time, we plan to use human immune responses directed against ocular bacteria to distinguish colonizing bacteria from transient bacteria that are likely washed away.
To further refine the understanding of ocular colonizing bacteria, we plan to inoculate germ-free (GF) and specific pathogen-free (SPF) mice with human ocular bacteria. After an extended period of time, we plan to re-isolate bacteria from the eyes of mice. Bacteria that are still present on the ocular surface will be considered to have a higher likelihood of being an ocular surface colonizer in humans. The development of a model such as this will allow others to assess the colonizing ability of other bacteria that may be considered a core component of the ocular surface microbiome.
In sum, data from our proposal will be a resource for the community at large because we will have:
1) Generated a robust set of ocular microbiome sequencing data that will provide information on the stability and consistency of ocular microbiome signatures,
2) Created a bank of bacteria that were acquired from healthy human eyes,
3) Defined protocols to use human immunity to measure the colonizing ability of bacteria,
4) Developed an in vivo animal model to assess how ocular bacteria can be inoculated and re-isolated from the eye.
These resources will be free to use for the community and will act as a base to further investigate how the ocular microbiome influences ocular surface health and disease.
Recent studies have shown data suggesting that the ocular microbiome exists and influences ocular surface health and disease. Despite this, defining the "core" components of the ocular surface microbiome has been difficult, largely due to the low biomass nature of the eye, a lack of robust data sets, reliance only on next-generation sequencing (NGS), and the inability to show causal relationships between microbes and host physiology.
Herein, we have outlined a proposal that directly addresses these knowledge gaps and that will lay the foundation for future studies aimed at investigating how the ocular surface microbiome influences health and disease. We have recruited a multidisciplinary research team that consists of experts in clinical and basic ophthalmology research, microbiome of low biomass sites, and immunology.
With this team, we plan to first characterize the healthy human ocular microbiome in two geographic locations (Pittsburgh and Miami) longitudinally (0, 1 week, 3 months) using molecular techniques (DNA and RNA sequencing) and culturomics. While molecular techniques will provide us with the broadest consortia of bacteria, culturomics will provide us with viable bacteria that we plan to bank in the Campbell Laboratory, so that bacteria from healthy human eyes can be a resource for the community in future studies.
Next, because immunity is normally generated towards components of the microbiome that remain associated with the host for extended periods of time, we plan to use human immune responses directed against ocular bacteria to distinguish colonizing bacteria from transient bacteria that are likely washed away.
To further refine the understanding of ocular colonizing bacteria, we plan to inoculate germ-free (GF) and specific pathogen-free (SPF) mice with human ocular bacteria. After an extended period of time, we plan to re-isolate bacteria from the eyes of mice. Bacteria that are still present on the ocular surface will be considered to have a higher likelihood of being an ocular surface colonizer in humans. The development of a model such as this will allow others to assess the colonizing ability of other bacteria that may be considered a core component of the ocular surface microbiome.
In sum, data from our proposal will be a resource for the community at large because we will have:
1) Generated a robust set of ocular microbiome sequencing data that will provide information on the stability and consistency of ocular microbiome signatures,
2) Created a bank of bacteria that were acquired from healthy human eyes,
3) Defined protocols to use human immunity to measure the colonizing ability of bacteria,
4) Developed an in vivo animal model to assess how ocular bacteria can be inoculated and re-isolated from the eye.
These resources will be free to use for the community and will act as a base to further investigate how the ocular microbiome influences ocular surface health and disease.
Funding Goals
1) TO SUPPORT EYE AND VISION RESEARCH PROJECTS THAT ADDRESS THE LEADING CAUSES OF BLINDNESS AND IMPAIRED VISION IN THE U.S. THESE INCLUDE RETINAL DISEASES, CORNEAL DISEASES, CATARACT, GLAUCOMA AND OPTIC NEUROPATHIES, STRABISMUS, AMBLYOPIA, AND LOW VISION AND BLINDNESS REHABILITATION. 2) TO INCREASE UNDERSTANDING OF THE NORMAL DEVELOPMENT AND FUNCTION OF THE VISUAL SYSTEM IN ORDER TO BETTER PREVENT, DIAGNOSE, AND TREAT SIGHT-THREATENING CONDITIONS, AND, TO ENHANCE THE REHABILITATION, TRAINING, AND QUALITY OF LIFE OF INDIVIDUALS WHO ARE PARTIALLY-SIGHTED OR BLIND. 3) TO SUPPORT A BROAD PROGRAM OF BASIC VISION RESEARCH THROUGH GRANTS AND COOPERATIVE AGREEMENTS, TO ENCOURAGE HIGH QUALITY CLINICAL RESEARCH, INCLUDING CLINICAL TRIALS, OTHER EPIDEMIOLOGICAL STUDIES, AND HEALTH SERVICES RESEARCH, TO ENCOURAGE RESEARCH TRAINING AND CAREER DEVELOPMENT IN THE SCIENCES RELATED TO VISION, AND TO SPONSOR SCIENTIFIC WORKSHOPS IN HIGH PRIORITY RESEARCH AREAS TO ENCOURAGE EXCHANGE OF INFORMATION AMONG SCIENTISTS. 4) SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO ENCOURAGE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Pittsburgh,
Pennsylvania
152221808
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 196% from $1,117,154 to $3,305,844.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education was awarded
Ocular Microbiome Stability Study: Defining Core Bacterial Members
Cooperative Agreement U24EY035102
worth $3,305,844
from National Eye Institute in July 2023 with work to be completed primarily in Pittsburgh Pennsylvania United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.867 Vision Research.
The Cooperative Agreement was awarded through grant opportunity A Community Research Resource: Characterization of the Resident Ocular Microbiome. (U24 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 8/20/25
Period of Performance
7/1/23
Start Date
6/30/26
End Date
Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
Activity Timeline
Transaction History
Modifications to U24EY035102
Additional Detail
Award ID FAIN
U24EY035102
SAI Number
U24EY035102-2763197757
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Other
Awarding Office
75NW00 NIH National Eye Institute
Funding Office
75NW00 NIH National Eye Institute
Awardee UEI
MKAGLD59JRL1
Awardee CAGE
1DQV3
Performance District
PA-12
Senators
Robert Casey
John Fetterman
John Fetterman
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,117,154 | 100% |
Modified: 8/20/25